Skip to content

US · MBIO · BIOTECHNOLOGY

Mustang Bio, Inc. (MBIO) intrinsic value and stock valuation

$0.35as of 2026-11-21 · Mkt cap 4.52M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Mustang Bio, Inc. DCF and intrinsic value

InvestorsCraft values MBIO with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBIO’s statements →

Mustang Bio, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Waltham, MA 02453 mustangbio.com

How the business is doing

Fiscal 2015–2025, USD

Revenue
$0.00
20152025
Net income
-$-1.92M
20152025
Free cash flow
-$-5.26M
20152025
Total equity
$9.53M-37.3% 5y CAGRd
20152025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2015–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-2.43M-$-16.25M-$-50.73M-$-76.16M-$-66.72M
Net income-$-1.92M-$-15.75M-$-51.6M-$-77.53M-$-66.37M
EPSd-$-391.04K-$-2.57M-$-6M-$-11.24M-$-11.33M
Operating cash flow-$-5.26M-$-11.41M-$-49.48M-$-65.07M-$-53.67M
Capital expenditure$0.00$0.00-$-110K-$-3.08M-$-5.37M
Free cash flow-$-5.26M-$-11.41M-$-49.59M-$-68.14M-$-59.03M
Total assets$17.6M$9.31M$17.7M$92.4M$125.2M
Total debt$0.00$880K$2.5M$31.4M$2.03M
Net debt-$-17.27M-$-5.96M-$-3.74M-$-44.27M-$-107.58M
Total equity$9.53M-$-3.87M$120K$46.3M$112.4M
Cash and short-term investments$17.3M$6.84M$6.23M$75.7M$109.6M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$40K$0.00$2.23M$3.03M$2.31M
Gross profit-$-40K$0.00-$-2.23M-$-3.03M-$-2.31M
Research and development expenses$1.52M$8.42M$39.2M$64M$53.5M
Selling, general and administrative expenses$3.95M$4.13M$9.32M$12.2M$11M
Other expenses-$-3.07M$3.69M$0.00-$-3.03M-$-140K
Operating expenses$2.39M$16.3M$48.5M$73.1M$64.4M
Cost and expenses$2.43M$16.3M$50.7M$76.2M$66.7M
Interest income$510K$180K$850K$690K$370K
Interest expense$0.00-$-10K$1.31M$3.36M$10K
Depreciation and amortization$40K$820K$2.23M$3.03M$2.31M
Ebitda-$-1.88M-$-14.92M-$-48.06M-$-71.14M-$-64.05M
Operating income-$-2.43M-$-16.25M-$-50.73M-$-76.16M-$-66.72M
Total other income/expenses, net$510K$490K-$-880K-$-1.37M$350K
Income before tax-$-1.92M-$-15.75M-$-51.6M-$-77.53M-$-66.37M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-1.92M-$-15.75M-$-51.6M-$-77.53M-$-66.37M
Weighted average shares outstanding$4.91M$6.13M$8.6M$6.9M$5.86M
Weighted average diluted shares outstanding$4.91M$6.13M$8.6M$6.9M$5.86M
Balance sheet
20252024202320222021
Cash and short-term investments$17.3M$6.84M$6.23M$75.7M$109.6M
Net receivables$220K$400K$3.88M$0.00$50K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$17.6M$8.61M$11.4M$78.9M$111.7M
Property, plant and equipment, net$0.00$450K$4.81M$12.3M$12.1M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$0.00$700K$6.4M$13.6M$13.5M
Total assets$17.6M$9.31M$17.7M$92.4M$125.2M
Accounts payable$3.51M$7.46M$6.32M$6.83M$3.51M
Short-term debt$0.00$460K$520K$610K$350K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$7.91M$12.6M$15.4M$15.1M$10.8M
Long-term debt$0.00$420K$1.98M$30.8M$1.69M
Deferred revenue, non-current$150K$150K$270K$0.00$270K
Total non-current liabilities$150K$570K$2.25M$31M$1.96M
Capital lease obligations$0.00$880K$2.5M$3.95M$2.03M
Total liabilities$8.06M$13.2M$17.6M$46.2M$12.8M
Common stock$0.00$10K$0.00$10K$10K
Retained earnings-$-398.64M-$-396.72M-$-380.97M-$-329.37M-$-251.84M
Accumulated other comprehensive income (loss)$270K$0.00$0.00$1.11M$0.00
Total equity$9.53M-$-3.87M$120K$46.3M$112.4M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$0.00$880K$2.5M$31.4M$2.03M
Net debt-$-17.27M-$-5.96M-$-3.74M-$-44.27M-$-107.58M
Cash flow statement
20252024202320222021
Net income-$-1.92M-$-15.75M-$-51.6M-$-77.53M-$-66.37M
Depreciation and amortization$40K$820K$2.23M$3.03M$2.31M
Stock-based compensation$130K-$-450K$570K$2.28M$3.31M
Change in working capital-$-1.68M-$-630K-$-2.98M$4.03M-$-640K
Accounts receivable$430K$490K-$-3.58M$10K-$-40K
Inventory$0.00$0.00$0.00-$-10K$40K
Accounts payable$0.00-$-2.97M$190K$5.3M-$-170K
Net cash provided by operating activities-$-5.26M-$-11.41M-$-49.48M-$-65.07M-$-53.67M
Investments in property, plant and equipment$0.00$0.00-$-60K-$-3.08M-$-5.37M
Acquisitions, net$0.00$0.00$0.00$130K$0.00
Net cash used for investing activities$1.17M$0.00$5.89M-$-2.95M-$-5.37M
Common stock issued$14.5M$9.15M$4.56M$6.62M$71.9M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00-$-610K$0.00$0.00$0.00
Net cash used for financing activities$14.5M$11.3M-$-26.08M$34.1M$70.9M
Net change in cash$10.4M-$-140K-$-69.67M-$-33.96M$11.8M
Cash at end of period$17.3M$6.84M$6.98M$76.7M$110.6M
Operating cash flow-$-5.26M-$-11.41M-$-49.48M-$-65.07M-$-53.67M
Capital expenditure$0.00$0.00-$-110K-$-3.08M-$-5.37M
Free cash flow-$-5.26M-$-11.41M-$-49.59M-$-68.14M-$-59.03M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Mustang Bio, Inc.

        Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.

        CEO
        Manuel Litchman
        Employees
        4
        Beta
        2.05

        Explore

        Frequently asked questions

        What is the intrinsic value of Mustang Bio, Inc. (MBIO)?

        InvestorsCraft does not currently publish an intrinsic value for MBIO. How the IC value is calculated.

        Is MBIO undervalued?

        InvestorsCraft does not publish an undervaluation signal for MBIO at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.